SHATTUCK LABS INC. - COMMON STOCK

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

21 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

13 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023

05 Dec 2023 16:15:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

14 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights

09 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

06 Nov 2023 09:28:40 By Nasdaq GlobeNewswire

Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting

02 Nov 2023 09:01:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights

10 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

25 May 2023 17:15:39 By Nasdaq GlobeNewswire

Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights

09 May 2023 16:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference

03 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting

16 Mar 2023 08:31:26 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming March Conferences

01 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates

23 Feb 2023 16:30:00 By Nasdaq GlobeNewswire

Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023

16 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference

09 Feb 2023 06:01:00 By Nasdaq GlobeNewswire

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023

09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights

08 Nov 2022 16:30:00 By Nasdaq GlobeNewswire

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

07 Nov 2022 08:01:11 By Nasdaq GlobeNewswire